Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

Formulation differentiates therapies in crowded markets by improving adherence, tolerability, convenience, and delivery efficiency.

Ultragenyx Pharmaceutical has received accelerated approval from the FDA for its gene therapy, Genglycos, to treat GSDIa.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

The EC has approved an extended use of Johnson & Johnson's Tecvayli, along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).